We invite you to attend the 3rd Antibody Drug Conjugates Conference, which will take place June 25-26, 2018 in Boston, MA. This event will bring together an exciting balance of industry and academia, so that delegates have the unique opportunity to network with colleagues from different sectors and gain a fresh perspective on the emergence of recent data from ADC clinical trials, new linkers and payloads, personalized healthcare, site specific attachment, and ADC therapeutics.
With the field of antibody drug conjugates rapidly expanding and the increasing number of ADC clinical trials, novel therapeutics are emerging. The ADC therapeutic area combines synthetic chemistry with rationale biology and is advancing monoclonal antibody treatments into the realm of precision medicine with improved effectiveness and therapeutic indices.
- Antibody and Protein Discovery Technologies
- Payloads, Linkers, and Alternative Strategies in ADCs
- Important Considerations During Preclinical Development
- Advances in Antibody Engineering
- Regulatory Considerations of Bringing Antibody Therapies to Market
We hope to see you there!
The 2018 Advisory Committee
|2017 Program Director|
|Victor-Jeffrey Leyton, Université de Sherbrooke|
|2017 Advisory Board Members|
|Neeraj Agrawal, Amgen|
|Ahuva Nissim, Queen Mary University|
|Amandeep Gakhal, Sutro Biopharma|
|Ann White, University of Southampton|
|Bill Harriman , Crystal Bioscience|
|Birgit Schoeberl, Merrimack Pharmaceuticals|
|Elad Firnberg, Revolve Biotechnologies|
|Ernesto Freire, Johns Hopkins University|
|Nicolas Fischer, Novimmune SA|
|Gregory Adams, Eleven Biotherapeutics|
|Janos Luka, Walter Reed Army Institute of Research|
|Matthew Robinson, Immunome, Inc|
|Michael R. Dyson, IONTAS Ltd|
|Andreas Pahl, Heidelberg Pharma|
|Pedro Berraondo López, CIMA, University of Navarra|
|Darren Schofield, MedImmune|
|Seema Kumar, EMD Serono|
|Jamshid Tanha, University of Ottawa|
|Thomas Pillow, Genentech|
|Medha J. Tomlinson, Abbvie|
|Yan Chen, Genentech|
Amber Kempf at 626-256-6405 or amber.kempf [at] gtcbio.com
Wyatt Technology is the recognized leader in instrumentation for determining the absolute molar mass, size, charge and interactions of macromolecules and nanoparticles in solution. These tools include: in-line multi-angle static light scattering, high-throughput dynamic light scattering, differential refractometry, electrophoretic mobility, differential viscosity, field flow fractionation and automated composition gradient.
Viracor Eurofins provides clinical trial biomarker testing services with expertise in custom assay transfer, design and validation for phase I-IV trials. Our CAP/CLIA and NY state accredited laboratory has over 30 years of experience in molecular testing, immune response monitoring, vaccine safety/efficacy assessment, allergy and hypersensitivity testing.